Artiva Biotherapeutics Inc. (ARTV) Stock Price, Quote & News

Company Profile

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vascul...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 267 4467

Website: www.artivabio.com

Address:

5505 Morehouse Drive, Suite 100, San Diego, United States

belugatrade Apr. 15 at 4:41 PM

$ARTV expanding

0 · Reply

BrianRix Apr. 15 at 2:51 PM

$ARTV should have bought at 6 last week. Now i don't want to chase

1 · Reply

iQuicky Apr. 15 at 2:23 PM

$ARTV support cure cancer companies

0 · Reply

swinda42 Apr. 15 at 12:39 PM

$ARTV going to the moon

0 · Reply

Astrid00 Apr. 9 at 3:41 PM

$ARTV $BTQ $NKTR $VWAV

0 · Reply

BladeWarden Apr. 9 at 3:30 PM

$NKTR $VWAV $ARTV $BTQ •45•

0 · Reply

focafoca99 Apr. 8 at 7:59 PM

$ARTV is just flagging its participation in the Needham virtual healthcare conference.

0 · Reply

Papermoon347 Apr. 7 at 11:18 AM

$ARTV Seems like its getting ready to explode! I believe if it pulls back first it will be very little I am waiting to add today ! Even with a bad market I bet we finish green today !

0 · Reply

RDequities Apr. 6 at 10:00 PM

$ARTV last time this was red ..can’t recall

1 · Reply

lovestockstwits Apr. 2 at 11:44 AM

$ARTV everyday up

0 · Reply

Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

Mar 10, 2026, 4:05 PM EDT - 5 weeks ago

Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights

Feb 25, 2026, 8:00 AM EST - 7 weeks ago

Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 8:00 AM EST - 7 weeks ago

Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant

Feb 19, 2026, 8:00 AM EST - 7 weeks ago

Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors

Jan 21, 2026, 8:00 AM EST - 3 months ago

Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL

Nov 12, 2025, 7:20 AM EST - 5 months ago

Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease

Nov 12, 2025, 7:00 AM EST - 5 months ago

Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 3, 2025, 4:05 PM EST - 5 months ago

Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK®

Oct 30, 2025, 4:17 PM EDT - 5 months ago

Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November

$Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update$

Oct 16, 2025, 4:05 PM EDT - 6 months ago

Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update

Aug 25, 2025, 4:05 PM EDT - 8 months ago

Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025

Aug 6, 2025, 4:05 PM EDT - 9 months ago

Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights

May 28, 2025, 4:05 PM EDT - 11 months ago

Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference

May 13, 2025, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

May 8, 2025, 8:00 AM EDT - 1 year ago

Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights

Apr 28, 2025, 4:35 PM EDT - 1 year ago

Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

Apr 8, 2025, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer

Mar 31, 2025, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 24, 2025, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

Feb 20, 2025, 4:05 PM EST - 1 year ago

Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

Jan 29, 2025, 4:05 PM EST - 1 year ago

Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D.

Nov 12, 2024, 4:05 PM EST - 1 year ago

Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 11, 2024, 4:05 PM EST - 1 year ago

Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference

Oct 22, 2024, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors

Sep 10, 2024, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference

Aug 29, 2024, 4:05 PM EDT - 1 year ago

Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 13, 2024, 2:14 PM EDT - 1 year ago

Artiva Biotherapeutics' Investigational Scalable Cell Therapies For Autoimmune Disorders, Analyst Initiate With Bullish Pitch

Jul 18, 2024, 7:08 PM EDT - 1 year ago

Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering

belugatrade Apr. 15 at 4:41 PM

$ARTV expanding

0 · Reply

BrianRix Apr. 15 at 2:51 PM

$ARTV should have bought at 6 last week. Now i don't want to chase

1 · Reply

iQuicky Apr. 15 at 2:23 PM

$ARTV support cure cancer companies

0 · Reply

swinda42 Apr. 15 at 12:39 PM

$ARTV going to the moon

0 · Reply

Astrid00 Apr. 9 at 3:41 PM

$ARTV $BTQ $NKTR $VWAV

0 · Reply

BladeWarden Apr. 9 at 3:30 PM

$NKTR $VWAV $ARTV $BTQ •45•

0 · Reply

focafoca99 Apr. 8 at 7:59 PM

$ARTV is just flagging its participation in the Needham virtual healthcare conference.

0 · Reply

Papermoon347 Apr. 7 at 11:18 AM

$ARTV Seems like its getting ready to explode! I believe if it pulls back first it will be very little I am waiting to add today ! Even with a bad market I bet we finish green today !

0 · Reply

RDequities Apr. 6 at 10:00 PM

$ARTV last time this was red ..can’t recall

1 · Reply

lovestockstwits Apr. 2 at 11:44 AM

$ARTV everyday up

0 · Reply

swinda42 Apr. 1 at 10:32 PM

$ARTV come on go to 25$ already

0 · Reply

swinda42 Apr. 1 at 1:01 PM

$ARTV

0 · Reply

SuperGreenToday Mar. 31 at 10:11 PM

$ARTV

0 · Reply

Think_Bigly Mar. 31 at 6:45 PM

$ARTV very few even know about this.. with RMAT from FDA.. will come to market.. https://www.biospace.com/press-releases/affimed-announces-acimtamig-and-allonk-combination-granted-regenerative-medicine-advanced-therapy-rmat-designation-by-the-u-s-food-and-drug-administration-fda

0 · Reply